Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 17/20 | 0.46 |
| ▸ | PDE2A | O00408 | 1/20 | 0.44 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18756230 | 1.00 | CHRM1 (0.46) | CHRM1PDE2APDE11AKMT2ASSTR3 | |
| SCHEMBL18725510 | 0.91 | CHRM1 (0.47) | CHRM1PDE2APDE11AKMT2A | |
| SCHEMBL18725367 | 0.88 | CHRM1 (0.51) | CHRM1PDE2APDE11A | |
| SCHEMBL17440045 | 0.87 | CHRM1 (0.50) | CHRM1SSTR3 | |
| SCHEMBL18725487 | 0.87 | CHRM1 (0.50) | CHRM1PDE2APDE11A | |
| SCHEMBL21235164 | 0.86 | CHRM1 (0.53) | CHRM1PDE2APDE11A | |
| SCHEMBL18725517 | 0.86 | CHRM1 (0.53) | CHRM1PDE2APDE11A | |
| SCHEMBL18756231 | 0.85 | KMT2A (0.51) | CHRM1KMT2A | |
| SCHEMBL21545734 | 0.84 | CHRM1 (0.44) | CHRM1PDE2APDE11AKMT2A | |
| SCHEMBL21545793 | 0.84 | CHRM1 (0.44) | CHRM1PDE2APDE11AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CHRM1 1/4885PDE2A 671/4885PDE11A 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.